Albumin News and Research

RSS

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

WSU researchers working on new system to reduce negative effects of cancer drugs

Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients.

19 Nov 2014

D-LIVER project aims to help patients with chronic liver disease

A European ICT for Health project aims to improve the quality of life of patients with chronic liver disease, by developing a remote support system to monitor their condition at home.

6 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Rutgers scientists are developing new medical imaging method for early detection of cancer

A new medical imaging method being developed at Rutgers University could help physicians detect cancer and other diseases earlier than before, speeding treatment and reducing the need for invasive, time-consuming biopsies.

22 Oct 2014

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.

8 Oct 2014

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA.

10 Sep 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

Inflammatory marker signals diabetic nephropathy development

Measuring serum levels of high-sensitivity C-reactive protein could help to predict which patients with Type 2 diabetes will develop renal disease, research suggests.

5 Sep 2014

Lifestyle intervention shows kidney benefits in diabetic patients

A lifestyle intervention focused on weight loss and increasing physical activity should be considered as additional treatment to prevent advanced kidney disease in overweight or obese people with Type 2 diabetes, say researchers.

28 Aug 2014

Hypertension control may ward off renal damage in diabetics

Elevated blood pressure is associated with an increased risk of renal damage in patients with Type 2 diabetes, especially if they have poor glycaemic control, study findings suggest.

4 Aug 2014

Albuminuria change is a strong cardiovascular risk indicator in diabetes

Changes in albuminuria predict cardiovascular mortality and morbidity over and above glucose levels and blood pressure, say researchers.

25 Jul 2014

Standard TFI definition still applies for relapsed SCLC classification

Italian researchers have confirmed that using a treatment-free interval cut-off of 60 days to classify relapsed small-cell lung cancer as sensitive or resistant can be regarded as the standard definition.

23 Jul 2014

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers.

4 Jul 2014

Five specific tests commonly performed in anesthesiology may not be necessary

Proving that less really is more, five specific tests or procedures commonly performed in anesthesiology that may not be necessary and, in some cases should be avoided, will be published online June 16 in JAMA Internal Medicine.

17 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.